Potential therapeutic value of drugs inhibiting semicarbazide-sensitive amine oxidase: Vascular cytoprotection in diabetes mellitus

Pharmacological Research

Volumn 37, Issue 2, 1998, Pages 87-92

  Ekblom, Jonas ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (COPPER CONTAINING); FORMALDEHYDE; GLYCINE; HYDROGEN PEROXIDE; METHYLAMINE; METHYLGLYOXAL; MONOAMINE OXIDASE INHIBITOR;

CARDIOVASCULAR DISEASE; CATALYSIS; CELL PROTECTION; DEAMINATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; PERIPHERAL NERVE; PRIORITY JOURNAL; REVIEW; VASCULAR SMOOTH MUSCLE;

EID: 0032005097     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1997.0272     Document Type: Article

References (68)

1. 1. Kohner EM, Porta M, Hyer SL. Pathogenesis of diabetic retinopathy and cataract. In: Pickup J, Williams G, eds. Textbook of Diabetes. Oxford: Blackwell Scientific Publications, 1991: pp. 564-574.
2. 2. Bacala R, Cerami A. Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34.
3. 3. Kennedy L, Bayes JW. Non-enzymatic glycosylation and the chronic complications in diabetes: an overview. Diabetologia 1984; 26: 93-8.
4. 4. Thornalley PJ, Westwood M, Lo TW, McLellan AC. Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes. Contrib Nephrol 1995; 112: 24-31.
5. 5. Biessels GJ, Van Dam PS. Diabetic neuropathy: pathogenesis and current treatment perspectives. Neurosci Res Commun 1996; 20: 1-10.
6. 6. Malik RA, Tesfaye S, Thompson S.D. Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetologia 1993; 36: 454-9.
7. 7. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-12.
8. 8. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-67.
9. 9. Hunt JV, Bottoms MA, Mitchinson MJ. Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation. Some fundamental differences in proposed mechanisms of glucose oxidation and oxidant production. Biochem J 1993; 291: 529-35.
10. 10. Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991; 10: 339-52.
11. 11. Hotta N. Symposium on treatment of diabetic complications. 1. Retinopathy. Intern Med 1997; 36: 136-8.
12. 12. Lo TW, Selwood T, Thornalley PJ. The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochem Pharmacol 1994; 48: 1865-70.
13. 13. Buffoni F. Properties, distribution and physiological role of semicarbazied-sensitive amine oxidases. Curr Top Pharmacol 1993; 2: 33-49.
14. 14. Lewinsohn R. Mammalian monoamine-oxidizing enzymes, with special reference to benzylamine oxidase in human tissues. Braz J Med Biol Res 1984; 17: 223-56.
15. 15. Banchelli G, Fantozzi R, Ignesti G, Pirisino R, Raimondi L, Buffoni F. The amine oxidase of human blood lymphocytes and granulocytes. Biochem Int 1983; 7: 89-94.
16. 16. Bond PA, Cundall RL. Properties of monoamine oxidase (MAO) in human blood platelets, plasma, lymphocytes and granulocytes. Clin Chim Acta 1977; 80: 317-26.
17. 17. Lewinsohn R, Bohm K, Glover V, Sandler M. A benzylamine oxidase distinct from monoamine oxidase B - widespread distribution in man and rat. Biochem Pharmacol 1978; 27: 1857-63.
18. 18. Lewinsohn R, Glover V, Sandler M. Development of benzylamine oxidase and monoamine oxidase A and B in man. Biochem Pharmacol 1980; 29: 1221-30.
19. 19. Lovenberg W, Dixon E, Keiser HR, Sjoerdsma A. A comparison of amine oxidase activity in human skin, rat skin and rat liver: relevance to collagen cross-linking. Biochem Pharmacol 1968; 17: 1117-20.
20. 20. Precious E, Lyles GA. Properties of a semicarbazide-sensitive amine oxidase in human umbilical artery. J Pharm Pharmacol 1988; 40: 627-33.
21. 21. Precious E, Gunn CE, Lyles GA. Deamination of methylamine by semicarbazide-sensitive amine oxidase in human umbilical artery and rat aorta. Biochem Pharmacol 1988; 37: 707-13.
22. 22. Blaschko H, Friedman PJ, Hawes R, Nilsson K. The amine oxidases of mammalian plasma. J Physiol 1959; 145: 384-404.
23. 23. Blaschko H. The natural history of amine oxidases. Rev Physiol Biochem Pharmacol 1974; 70: 84-128.
24. 24. Kapeller-Adler R. Amine oxidases and methods for their study. New York: John Wiley, 1970.
25. 25. Mu D, Medzihradszky KF, Adams GW. Primary structures for a mammalian cellular and serum copper amine oxidase. J Biol Chem 1994; 269: 9926-32.
26. 26. Zhang X, McIntire WS. Cloning and sequencing of a copper-containing, topa quinone-containing monoamine oxidase from human placenta. Gene 1996; 179: 279-86.
27. 27. Imamura Y, Kubota R, Wang Y. Human retina-specific amine oxidase (RAO): cDNA cloning, tissue expression, and chromosomal mapping. Genomics 1997; 40: 277-83.
28. 28. Buffoni F, Blaschko H. Benzylamine oxidase and histaminase: purification and crystallization of an enzyme from pig plasma. Proc Roy Soc Lond 1964; 161: 153-67.
29. 29. McEwen CM, Jr. Human plasma monoamine oxidase. 1. Purification and identification. J Biol Chem 1965; 240: 2003-10.
30. 30. Nilsson S, Tryding N, Tufvesson G. Serum monoamine oxidase (MAO) in diabetes mellitus. Acta Med Scand 1967; 184: 29-31.
31. 31. Tryding N, Nilsson SE, Tufvesson G. Physiological and pathological influences on serum monoamine oxidase level. Effect of age, sex, contraceptive steroids and diabetes mellitus. Scand J Clin Lab Invest 1969; 23: 79-84.
32. 32. Boomsma F, Derkx FH, van den Meiracker AH, Man in 't Veld AJ, Schalekamp MA. Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated hemoglobin. Clin Sci 1995; 88: 675-9.
33. 33. Hayes BE, Clarke DE. Semicarbazide-sensitive amine oxidase activity in streptozotocin diabetic rats. Res Commun Chem Pathol Pharmacol 1990; 69: 71-83.
34. 34. Elliott J, Fowden AL, Callingham BA, Sharman DF, Silver M. Physiological and pathological influences on sheep blood plasma amine oxidase: effect of pregnancy and experimental alloxan-induced diabetes mellitus. Res Vet Sci 1991; 50: 334-9.
35. 35. Boor PJ, Trent MB, Lyles GA, Tao M, Ansari GA. Methylamine metabolism to formaldehyde by vascular semicarbazide-sensitive amine oxidase. Toxicology 1992; 73: 251-8.
36. 36. Yu PH, Zuo DM. Aminoguanidin inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications. Diabetologia 1997; 40: 1243-50.
37. 37. Ceriello A, Quatraro A, Caretta F, Varano RDG. Evidence for a possible role of oxygen free radicals in the abnormal functional arterial vasomotion in insulin dependent diabetes. Diabetes Metabol 1990; 16: 318-22.
38. 38. Taniguchi N, Kaneto H, Asahi M. Involvement of glycation and oxidative stress in diabetic macroangiopathy. Diabetes 1996; 45: S81-3.
39. 39. Jensen T, Deckert T. Diabetic retinopathy, nephropathy and neuropathy. Generalized vascular damage in insulin-dependent diabetic patients. Horm Metab Res Suppl 1992; 26: 68-70.
40. 40. McLennan SV, Fisher EJ, Yue DK, Turtle JR. High glucose concentration causes a decrease in mesangium degradation: a factor in the pathogenesis of diabetic nephropathy. Diabetes 1994; 43: 1041-5.
41. 41. Lo TW, Westwood ME, McLellan AC, Selwood T, Thornalley PJ. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. J Biol Chem 1994; 269: 32299-305.
42. 42. Riley ML, Harding JJ. The reaction of methylglyoxal with human and bovine lens proteins. Biochim Biophys Acta 1995; 1270: 36-43.
43. 43. Ratliff DM, Vander Jagt DJ, Eaton RP, Vander Jagt DL. Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II - a clinical research center study. J Clin Endocrinol Metab 1996; 81: 488-92.
44. 44. Bird MI, Nunn PB, Lord L. Formation of glycine and aminoacetone from L-threonine by rat liver mitochondria. Biochim Biophys Acta 1984; 802: 229-36.
45. 45. Bird MI, Nunn PB. Glycine formation from L-threonine in intact isolated rat liver mitochondria. Biochem Soc Trans 1979; 7: 1276-7.
46. 46. Lyles GA, McDougall SA. The enhanced daily excretion of urinarymethylaminein rats treated with semicarbazide or hydralazin may related to the inhibition of semicarbazide-sensitive amine oxidase activities. J Pharm Pharmacol 1989; 42: 332-8.
47. 47. Yu PH, Zuo DM. Oxidative deamination of methylamine by semicarbazide-sensitive amine oxidase leads to cytotoxic damage in endothelial cells. Possible consequences for diabetes. Diabetes 1993; 42: 594-603.
48. 48. Yu PH, Lai CT, Zuo DM. Formation of formaldehyde from adrenaline in vivo; a potential risk factor for stress-related angiopathy. Neurochem Res 1997; 22: 615-20.
49. 49. Buffoni F. Histaminase and related amine oxidases. Pharmacol Rev 1966; 18: 1163-99.
50. 50. Arai Y, Toyoshima Y, Kinemuchi H. Studies of monoamine oxidase and semicarbazide-sensitive amine oxidase. II. Inhibition by alpha-methylated substrate-analogue monoamines, alpha-methyltryptamine, alpha-methylbenzylamine and two enantiomers of alpha-methylbenzylamine. Jpn J Pharmacol 1986; 41: 191-7.
51. 51. Kinemuchi H, Morikawa F, Ueda T, Arai Y. Studies of monoamine oxidase and semicarbazide-sensitive amine oxidase. I. Inhibition by a selective monoamine oxidase-B inhibitor, MD 780236. Jpn J Pharmacol 1986; 41: 183-9.
52. 52. Elliott J, Callingham BA, Barrand MA. In-vivo effects of (E)-2-(3′,4′-dimethoxyphenyl)-3-fluoroallylamine (MDL 72145) on amine oxidase activities in the rat. Selective inhibition of semicarbazide-sensitive amine oxidase in vascular and brown adipose tissues. J Pharm Pharmacol 1989; 41: 37-41.
53. 53. Banchelli G, Bertocci B, Buffoni F. A selective inhibitor of plasma benzylamine oxidase and of tissue semicarbazide sensitive amine oxidases (SSAO). Pharmacol Res Commun 1988; 20 [Suppl. 4]: 165.
54. 54. Bertini V, De Munno A, Lucchessini F. Aimed synthesis of selective inhibitors of copper containing amine oxidases. Pharm Res Commun 1988; 20 [Suppl. 4]: 163-4.
55. 55. Boomsma F, van den Meiracker A, Man in 't Veld A, Schalekamp M. Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease. Life Sci 1995; 57: 1753-9.
56. 56. Coelho H, Azevedo M, Manso C. Inhibitory effect of drugs used in the treatment of Parkinson's disease on plasma monoamine oxidase activity. J Neural Transm 1985; 61: 271-7.
57. 57. Lyles GA, Callingham BA. In vitro and in vivo inhibition by benserazide of clorgyline-resistant amine oxidases in rat cardiovascular tissues. Biochem Pharmacol 1982; 31: 1417-24.
58. 58. Lyles GA, Callingham BA. Hydralazine is an irreversible inhibitor of the semicarbazide-sensitive, clorgyline-resistant amine oxidase in rat aorta homogenates. J Pharm Pharmacol 1982; 34: 139-40.
59. 59. Lizcano JM, Fernandez de Arriba A, Tipton KF, Unzeta M. Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives. Biochem Pharmacol 1996; 52: 187-95.
60. 60. Lyles GA, Garcia-Rodriguez J, Callingham BA. Inhibitory actions of hydralazine upon monoamine oxidizing enzymes in the rat. Biochem Pharmacol 1983; 32: 2515-21.
61. 61. Barrand MA, Callingham BA. The interaction of hydralazine with a semicarbazide-sensitive amine oxidase in brown adipose tissue of the rat. Biochem J 1985; 232: 415-23.
62. 62. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-32.
63. 63. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 1994; 37: 32-5.
64. 64. Buffoni F, Della Corte L. Pig plasma benzylamine oxidase. Adv Biochem Psychopharmacol 1972; 5: 133-49.
65. 65. Yu PH. Deamination of methylamine and angiopathy: toxicity of formaldehyde, oxidative stress and relevance to glycoxidation in diabetes. In: Youdim MBH, Finberg JPM, Riederer P, Tipton KF, eds. 7th Amine Oxidase Workshop. Haifa, Israel, 1996.
66. 66. Crosbie AE, Callingham BA. Semicarbazide-sensitive amine oxidases in sheep plasma: interactions with some substrates and inhibitors. J Neural Transm 1994; 41 [Suppl]: 427-32.
67. 67. Lin AM, Castell DO. Comparative studies on human plasma MAO in normal subjects and in fibrotic liver disease. Biochem Med 1974; 9: 373-85.
68. 68. Lin AM, Castell DO. Multiple forms of monoamine oxidase in human plasma. Biochem Med 1975; 13: 141-56.